Abstract:The targeting of 5-aminosalicylic acid (5-ASA), a first-line therapeutic agent for mild to moderate active ulcerative colitis (UC), to the site of inflammation has remained a challenge and an unmet requirement in the treatment of UC. However, nanoscale carriers for targeted drug delivery are promising for pharmacotherapy, and nanoparticles improve the pharmacokinetics of the loaded therapeutics based on their physical properties. To design and prepare 5‑ASA‑loaded silicon dioxide nanoparticles (5‑ASA‑SiO2 NPs), a micro‑emulsion method was conducted, and their respective therapeutic effects were validated in a mouse model of UC. Cytotoxicity of 5‑ASA‑SiO2 NPs was detected in vitro using the Cell Counting Kit‑8 method. The therapeutic effect of 5‑ASA‑SiO2 NPs was assessed based on their disease activity index (DAI), colon histopathology, myeloperoxidase (MPO) and levels of tumor necrosis factor‑α (TNF‑α) and interleukin‑6 (IL‑6). SiO2 NPs were successfully prepared, and cytotoxicity of 5‑ASA‑SiO2 NPs was identified as being similar to 5‑ASA and SiO2 NPs. DAI and colonic histopathology scores in the normal dosage, high dosage and the 5‑ASA‑SiO2 NP groups demonstrated a significant improvement when compared with the model group. DAI in the high dosage and 5‑ASA‑SiO2 NP groups also demonstrated a significant improvement when compared with the normal dosage group. However, MPO, serum IL‑6 and TNF‑α levels in normal dosage, high dosage and 5‑ASA‑SiO2 NPs groups were significantly lower than in the model group, and these indexes in the high dosage group and 5‑ASA‑SiO2 NP group were significantly lower than that in the normal dosage group. Expression of IL‑6 and TNF‑α mRNA in colonic mucosa in the normal dosage, high dosage and 5‑ASA‑SiO2 NP group was significantly lower than that in the model group. Colonic mucosal IL‑6 and TNF‑α mRNA expression in the high dosage and 5‑ASA‑SiO2 NP groups was significantly lower than that in the normal dosage group (P<0.05). In conclusion, 5‑ASA‑SiO2 NPs are a selective drug release system that target the inflamed colon, characteristics of UC, and can greatly increase therapeutic efficacy in UC.

Colon-targeted Drug Delivery Systems for 5-Aminosalicylic Acid

SYNTHESIS AND IN VITRO BIODEGRADATION OF AZO POLYMER FOR COLON-SPECIFIC DRUG DELIVERY

Degradability of the Linear Azo Polymer Conjugated 5,5′‐azodisalicylic Acid Segment in the Main Chain for Colon‐specific Drug Delivery

Site-specific Targeted Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease.

Design strategies, advances and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease

Study on 5-Aminosalicylic Acid Coated Tablets Colonic Targeti Ng Drug Delivery System

Colon-targeting mutual prodrugs of 5-aminosalicylic acid and butyrate for the treatment of ulcerative colitis

Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery: in vivo study with ulcerative colitis targeting therapy in mice.

Sustained release of 5-aminosalicylic acid from azoreductase-responsive polymeric prodrugs for prolonged colon-targeted colitis therapy

Synthesis, Colon-Targeted Studies and Pharmacological Evaluation of an Anti-Ulcerative Colitis Drug 4-Aminosalicylic Acid-Β-o-glucoside.

Synthesis and Evaluation of a Prodrug of 5-Aminosalicylic Acid for the Treatment of Ulcerative Colitis.

New Understanding of Mechanisms of Action of 5-Aminosalicylic Acid in Inflammatory Bowel Disease and its Relevant Colorectal Cancer

Eudragit S100 coated iron oxide-chitosan nanocomposites for colon targeting of 5-aminosalicylic acid ameliorate ulcerative colitis by improving intestinal barrier function and inhibiting NLRP3 inflammasome

5-aminosalicylic acid pH sensitive core-shell nanoparticles targeting ulcerative colitis

Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease

Advances in Carotenoid Based Delivery Systems for Alleviating Inflammatory Bowel Disease

A Survey of Drug Delivery System for Inflammatory Bowel Disease

Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies

5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice

5-Aminosalicylic acid ameliorates dextran sulfate sodium-induced colitis in mice by modulating gut microbiota and bile acid metabolism

Harnessing polymer-derived drug delivery systems for combating inflammatory bowel disease